PDSB
$12.05
Pds Biotechnology
$.02
.17%
PDSB
Earnings Whisper ®
N/A
3rd Quarter September 2021
Consensus:  ($0.22)
Revenue:  $0.00 Mil
Wednesday
Nov 10
7:05 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when PDSB reports earnings?
Beat
Meet
Miss

Where is PDSB's stock price going from here?
Up
Flat
Down
Stock chart of PDSB
Analysts
Summary of analysts' recommendations for PDSB
Score
Grade
Pivots
Resistance
$12.92
$12.63
$12.34

$12.05

Support
$11.76
$11.47
$11.18
Tweet
Growth
Description
PDS Biotechnology Corp. is an immuno-oncology company. It is focused on developing a pipeline of clinical-stage immunotherapies to treat cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, cancer and other cancers. The company's products are based on the proprietary Versamune(R) platform technology, which activates and directs the human immune system. PDS Biotechnology Corp, formerly known as Edge Therapeutics Inc., is based in Berkeley Heights, United States.